Brief: Celldex Reports Results From Mid Stage Study Of Barzolvolimab In Eosinophilic Esophagitis
19/08/2025 21:03
Aug 19 (Reuters) - Celldex Therapeutics Inc CLDX.O: CELLDEX REPORTS RESULTS FROM PHASE 2 STUDY OF BARZOLVOLIMAB IN EOSINOPHILIC ESOPHAGITIS (EOE) CELLDEX THERAPEUTICS INC - PRIMARY ENDPOINT MET, NO IMPROVEMENT IN EOE SYMPTOMS CELLDEX THERAPEUTICS INC - BARZOLVOLIMAB SHOWS FAVORABLE SAFETY PROFILE AT 300 MG Q4 WEEKLY CELLDEX THERAPEUTICS INC - WILL NOT ADVANCE DEVELOPMENT IN EOE Source text: ID:nGNX9RVxPB Further company coverage: CLDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials